Ovarian Cancer – NCI-04-C-0232
Dr. Elise C. Kohn
Principal Investigator
NCI is currently conducting the following trial for patients with ovarian, fallopian, or peritoneal cancer. Click on the trial below for additional details, including a summary of eligibility criteria, treatment plan, and information on how to contact Dr. Kohn and her staff directly.
You may also call the Clinical Trials Referral Office at 1-888-NCI-1937 (1-888-624-1937) to inquire about referring a patient to this trial.
- Physical exam and blood collection (including CA-125 testing) every 3 months
- CT scan of the abdomen and pelvis (and chest if indicated) every 6 months
- Patients with clinical evidence of disease relapse may undergo biopsy of the tumor
- The blood and urine samples collected during the study will be frozen until an adequate number of samples are available for analysis
- Quality of life is assessed at baseline and then every 3 months for up to 4 years or until disease relapse
Why is this trial important?
This trial enrolls women in first clinical remission from ovarian cancer. The study will employ proteomic profiling to identify a protein signature in the blood that might predict relapse of ovarian cancer before the cancer becomes visible on CT scan or physical exam. In the future, the signature might then be tested in the diagnostic setting in order to detect ovarian cancer in its early stage, when it is best amenable to cure.
Back to Top
